Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients

Bone Marrow Transplant. 2021 Mar;56(3):745-748. doi: 10.1038/s41409-020-01073-0. Epub 2020 Oct 2.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antilymphocyte Serum
  • Azithromycin
  • Graft vs Host Disease*
  • Hematologic Neoplasms* / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Recurrence
  • Transplant Recipients
  • Transplantation Conditioning
  • Unrelated Donors

Substances

  • Antilymphocyte Serum
  • Azithromycin